trial · primary record
Glofitamab
Diffuse Large B Cell Lymphoma (DLBCL)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2028-01 |
| Primary endpoint | evaluate the complete response rate (CRR) |
| Registry ID | NCT06765317 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:46.697Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06765317
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.